These drugs include nivolumab, pembrolizumab, and cemiplimab as PD-1 inhibitors for metastatic melanoma and non-small cell lung cancer (NSCLC) treatment; however, the latter is explicitly approved for advanced cutaneous squamous cell carcinoma [2]. This evidence concerns the gene PDCD1 and metastatic melanoma.